Prognostic stratification in pulmonary hypertension: A multi-biomarker approach.

Introduction: Pulmonary hypertension (PH) covers a group of conditions characterized by an increase in pulmonary vascular resistance leading to right ventricular failure. Risk stratification is crucial for adequate prognostic and therapeutic assessment. However, the accuracy of conventional parameters is limited, especially biomarkers.

Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction.

Background: MicroRNAs (miRNAs) are key players in cardiovascular development and disease. However, not only miRNAs of a cardiac origin have a critical role in heart function. Recent studies have demonstrated that miR-122-5p, a hepatic miRNA, increases in the bloodstream during ischemic cardiogenic shock and it is upregulated in the infarcted myocardium.

An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1.

Background: Pulmonary arterial hypertension (PAH) is a rare, deadly condition. Although risk stratification is extremely important for assessment of prognosis and to guide therapy, there is lack of evidence concerning the role of novel biomarkers. In a pivotal study, we sought to comparatively investigate the predictive power of several new biomarkers in PAH.

Nephropathy induced by contrast medium in an hispanic population after coronary angiography.

Unlabelled: Contrast medium-induced nephropathy (CIN) is regarded as one of the most important complications after intravascular administration of radiographic contrast media and the third most common cause of hospital-acquired acute kidney injury. Contrast-induced nephropathy may develop in up to10% of patient with normal renal function but may be as high 25% in patient with risk factors.

Methods: A total of 192 medical records were obtained, in which 55 patient were eligible by our inclusion and exclusion criteria.

Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations.

Oral anticoagulant therapy remains one of the most frequent options for treatment and prevention in patients with arterial and venous thromboembolism. Clinical guidelines have been updated in recent years by various associations such as the American Heart Association (AHA), the American College of Cardiology (ACC) and the European Society of Cardiology (ESC), as well as organizations in several other countries. The authors present a review of therapy with vitamin K antagonists, focusing on their mechanism of action and metabolism, as well as on the fundamentals of such therapy.